Skip to main content
. 2021 Nov 19;11:740762. doi: 10.3389/fonc.2021.740762

Figure 5.

Figure 5

The OS rate of non-comparative studies for HR with downstaging therapies in patients with HCC (A), the 5-year OS rate of non-comparative studies for HR with downstaging therapies stratified by mono/multitherapy (B), the 3-year OS rate of non-comparative studies for HR with downstaging therapies stratified by EHD included/excluded (C), the 5-year OS rate of non-comparative studies for HR with downstaging therapies stratified by EHD included/excluded (D). EHD, extrahepatic disease.